ArticleInternal medicine journal2026
Influence of MASLD and MAFLD on long-term extrahepatic cancer incidence and cancer mortality in regional Australia.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsMetabolic (dysfunction)-associated steatotic liver disease (MASLD) has been linked to an increased risk of extrahepatic cancers. Whether MASLD or metabolic (dysfunction)-associated fatty liver disease (MAFLD) is associated with an increased risk of extrahepatic cancer incidence or death in Australia is unknown.
methodsThis was a study from the Crossroads 1 cohort, enrolling randomly selected adults from regional Australia between 2001 and 2003 to partake in a comprehensive evaluation of health. MASLD is defined as fatty liver index (FLI) ≥60, one metabolic risk factor and no alternate liver disease, while MAFLD was defined as FLI ≥60 with overweight/obesity, type 2 diabetes mellitus (T2DM) and/or metabolic dysfunction. Longitudinal outcomes linked through cancer registry, hospital admission and death registry datasets and defined according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision codes.
resultsIn total, 1324 and 1444 participants respectively are included in the MASLD and MAFLD analyses. Prevalence was 35.4% (MASLD) and 40.7% (MAFLD). Median follow-up time was 19.7 years (interquartile range 19.1-20.1). Neither form of fatty liver disease (FLD) was associated with an increased risk of death related to extrahepatic cancer compared to those without FLD. Both forms of FLD were associated with an increased incidence of colorectal cancer (MASLD adjusted sub-hazard ratio (sHR) 2.90, 95% CI 1.17-7.17; MAFLD: sHR 3.15, 95% CI 1.43-6.96) following adjustment for confounding factors. This was primarily influenced by a difference seen among females (sHR 3.89-4.32).
conclusionNeither MASLD nor MAFLD was associated with an increased risk of extrahepatic cancer-related death, but they were associated with an increased risk of colorectal cancer incidence, particularly among females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.